Dont Get Blindsided: The Critical Drug Patent Mistakes That Can Sink M&A Due Diligence in Massachusetts
In life sciences M&A, the deal can look perfect on paperuntil a single patent detail turns a strategic acquisition into a costly scramble.
M…

Post-approval patents are supposed to be the aftercare of innovationextensions, tweaks, and new claims that keep therapies protected as they move from launch into real-world use. But for brand teams, generics counsel, and investors, theres a quieter st…

Post-Approval Patents: The Hidden Loe Risk Map Pharma Cant Afford to Ignore
Most teams think the patent story ends at approval.
They shouldnt.
In the post-approval world, the real risk often hides in plain sight: patents that are filed, asserted, or st…

Beyond 20 Years: What Actually Determines a Drugs Market Exclusivity
The public conversation about drug exclusivity often starts and ends with a single number: 20 years. Its a clean headline. Its also a misleading shortcut.
In reality, the lengthand ev…

Pharma mega-deals dont start with spreadsheets. They start with exclusivity.
If youve ever wondered why two companies can look at the same asset and arrive at wildly different valuations, the answer is often hiding in plain sight: the patchwork of lega…

Patent cliffs arent just a legal eventtheyre a pricing event.
If youre in pharma, biotech, payer strategy, or investment research, you already know the headlines: when exclusivity ends, generic and biosimilar competition can arrive fast, and prices c…

Post-Approval Isnt the Finish LineIts When Your Patent Strategy Gets Real
In pharma, the most expensive mistake is often the one made after approval.
Companies celebrate the launch, breathe out, and assume the hard part is over. But the regulatory and …

Post-approval is where the real IP game starts.
Most teams obsess over getting to approval—then quietly assume the hard part is over. It isn’t. In the months and years after launch, your product becomes a target: for generic challengers, for “evergre…

Pharma companies dont lose exclusivity because they missed a deadline. They lose it because they mismanaged the legal perimeter.
In todays generic and biosimilar landscape, defending patent exclusivity isnt just a regulatory exerciseits a litigation st…

From Humira to Keytruda: The Blueprint for Surviving the Composition of Matter Cliff
If you work in pharma, youve felt it: the moment the calendar starts to look like a countdown. Not because science suddenly stopsbut because patents do.
The compositio…